HER2基因突变晚期非小细胞肺癌治疗进展

肺癌是全球范围内一种高发病率和高死亡率的恶性肿瘤，非小细胞肺癌（NSCLC）是最常见的亚型，发生率约85%。人表皮生长因子受体2（HER2）是受体酪氨酸激酶（RTK）的重要成员之一，NSCLC中HER2基因主要表现为HER2突变、HER2扩增和HER2过表达三种形式。目前，靶向HER2突变的酪氨酸激酶抑制剂、单克隆抗体和抗体偶联药物在HER2突变的NSCLC中显示出一定的临床疗效，但相关免疫治疗疗效有限。本文就HER2突变相关NSCLC的治疗进展进行综述，以期为进一步完善HER2突变晚期NSCLC临床诊疗策略提供理论依据。

Progress of treatment for HER2 mutation in advanced non-small cell lung cancer

Lung cancer is a kind of malignant tumor with high morbidity and mortality in the world. The most common subtype is non-small cell lung cancer (NSCLC) which accounts for 85% in lung cancer. Human epidermal growth factor receptor-2 (HER2) is one of the most important members of receptor tyrosine kinase (RTK). In NSCLC, HER2 gene is mainly expressed in three phenotypes: HER2 mutation, HER2 amplification and HER2 overexpression. At present, the drugs targeting HER2 mutation, including tyrosine kinase inhibitors, monoclonal antibodies and antibody-drugs conjugates, have shown clinical efficacy in HER2 mutation NSCLC patients. However, the clinical efficacy of immunotherapy is limited. In this review, we discussed the progress of treatment in HER2 mutation NSCLC, so as to provide a theoretical basis for further clinical treatment strategy of advanced non-small cell lung cancer patients with HER2 mutation.